BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family
Provided By GlobeNewswire
Last update: Dec 17, 2024
SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the commercial availability of its Morph DNA steerable introducer product family, currently utilized in the Company’s ongoing cell-therapy clinical trials.
Read more at globenewswire.com
